Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

Trials
Home›Trials›Progression of rare connective tissue tumor controlled by targeted therapy

Progression of rare connective tissue tumor controlled by targeted therapy

By Ramoju kishore kumar
December 26, 2018
634
0
Share:

 

A drug called sorafenib stopped progression of desmoid tumors for 80 percent of patients taking the drug over a time of two years as a part of phase 3 trial.

Desmoid tumors which is well known as aggressive fibromatosis. They grow abnormally in the connective tissue and has a capability of impacting anywhere in the body. these tumors are not considered cancerous, because they do not spread to other parts of the body. They do not often cause death, but these tumors can cause significant health problems by invading surrounding tissues, causing pain, limiting mobility, and interfering with organ function. About 1,000 new cases, mostly in young adults, are diagnosed in the U.S. each year.

Desmoid tumors are very complex and display a wide range of behaviors, even in the same patient. Some tumors shrink spontaneously, some remain stable, while still others grow aggressively. Treatment varies from patient to patient. In the past, most patients were treated with surgery, but because there is a high risk that the tumor will return, surgery is now mainly used for tumors that are thought to have a low risk of recurrence. Radiation, chemotherapy, and hormonal treatments are sometimes effective in reducing tumor size and alleviating pain.

In this randomized, double-blinded trial, 87 patients with progressive, symptomatic, or recurrent desmoid tumors were given either oral sorafenib or placebo until scans showed disease progression.

Sorafenib is a targeted therapy that acts on tyrosine kinases — enzymes that have been implicated in cancer development — to inhibit the growth of cancer cells and the formation of new blood vessels that support tumor development. The drug has been approved by the FDA to treat certain types of advanced kidney, liver, and thyroid cancer. It has not yet been approved for the treatment of desmoid tumors.

The study is ongoing, but the researchers estimate that progression-free survival after two years is 81 percent in those taking sorafenib, and only 36 percent in those taking placebo. “This is a truly remarkable outcome,” says Schwartz, who is also a professor of oncology at Columbia University Vagelos College of Physicians and Surgeons. “In fact, we have never seen results like this in the treatment of desmoid tumors.”

Side effects, including rash, hypertension, and diarrhea, were more common in patients taking sorafenib than in those taking placebo.

The study was designed to measure sorafenib’s effect on progression-free survival. It did not address whether the drug led to meaningful improvements in pain or other symptoms.

In addition, 22 percent of patients in the treatment group discontinued therapy due to adverse events, such as fatigue and rash.

Additional clinical trials are needed to identify the optimal dosage to reduce the risk of treatment-related adverse events and determine whether an increase in progression-free survival also leads to improvements in pain relief, function, and quality of life.

Researchers are currently analyzing tumor samples obtained in this trial to better understand how sorafenib affects desmoid tumors at the molecular and cellular levels. Understanding sorafenib’s mechanism of action could lead to the development of additional therapies in the future.

TagsClinical trialsDesmoid tumorsfdaNon Cancerous
Previous Article

Can Psoriasis increase the risk of Type ...

Next Article

Govt Circular Released : Ph.D. Mandatory From ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0
User Avatar

Ramoju kishore kumar

Related articles More from author

  • BLOGS

    FDA approves pill with sensor

    November 15, 2017
    By admin
  • FDA AlertsMedical & HealthMedical research

    FDA approves a new clinical trial for non-healing wounds.

    October 28, 2017
    By admin
  • FDA Alerts

    FDA approves a new drug to treat malaria which could help millions.

    July 24, 2018
    By Sriram Nagarajan
  • BLOGS

    Treating Hereditary blindness by gene therapy will be a revolution in medical field

    October 20, 2017
    By admin
  • Uncategorized

    FDA approve new robotically-assisted surgical device for adult patients

    October 21, 2017
    By admin
  • FDA Alerts

    FDA Approves Humanized Monoclonal Antibody For Migraine Treatment.

    September 30, 2018
    By Sriram Nagarajan

Leave a reply Cancel reply

You may interested

  • BLOGS

    Record Numbers of FDA‑Approved Drugs: Recent Trends

  • PublicationsUncategorized

    List of UGC Approved journals 2020

  • BLOGS

    State-wise List of fake Universities as on June, 2017 as per UGC

  • LATEST REVIEWS

  • TOP REVIEWS

  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • August 3, 2023

    List of UGC declared 20 universities as fake, not authorised to award degrees.

  • July 28, 2023

    Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • May 24, 2021

    LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

  • October 20, 2020

    List of UGC Approved journals 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

Latest Comments

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC declared 20 universities as fake, not authorised to award degrees.

    By mythandintegrity
    August 3, 2023
  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

    By mythandintegrity
    July 28, 2023
  • LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

    By admin
    May 24, 2021
  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.